Lara A. Dunn, MD

Dr. Dunn describes how she uses immune checkpoint inhibitors in locally advanced cutaneous squamous cell carcinoma, distinguishing neoadjuvant therapy from checkpoint blockade given as a replacement for curative therapy.

Gino K. In, MD, MPH, of the USC Norris Comprehensive Cancer Center, and Lara A. Dunn, MD, of Memorial Sloan Kettering Cancer Center, open a discussion of newly reported long-term follow-up data on cosibelimab in locally advanced cutaneous squamous cell carcinoma.